Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

184.06 +5.73 (+3.22%)
Streaming Delayed Price Updated: 10:30 AM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Belite Bio, Inc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
From Belite Bio, Inc
Via GlobeNewswire
InvestorNewsBreaks – Belite Bio, Inc (NASDAQ: BLTE) Prices $350M Underwritten Public Offering of ADSs
Via Investor Brand Network
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Earnings Outlook For Belite Bio ↗
 
Via Benzinga
News headline image
Belite Bio's Earnings Outlook ↗
 
Via Benzinga
News headline image
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Why Belite Bio Stock Soared on Monday ↗
The company is now tantalizingly close to commercializing its leading drug candidate. 
Via The Motley Fool
News headline image
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Top movers in Monday's pre-market session ↗
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
From Belite Bio, Inc
Via GlobeNewswire
News headline image
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
From Virtual Investor Conferences; Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the 2025 Maxim Growth Summit
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
From Belite Bio, Inc
Via GlobeNewswire
News headline image
3 Lesser-Known Healthcare Names With Major Upside in Store ↗
These are three healthcare stocks offering a compelling combination of secure business, strong fundamentals, and growth opportunity. 
Via MarketBeat
News headline image
Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in Three Upcoming Investor Conferences
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Registered Direct Offering of $15 Million
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.